Inoviq Ltd has released a press release.
Positive SubB2M IHC Results for Melanoma
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Inoviq
- hTERT US Patent Granted
- INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out
- SubB2M US Patent Grant and Program Update
- Australian Patent Granted for SubB2M Technology
- INOVIQ Key Manufacturing Agreement to Advance SubB2M tests
Later from Inoviq
- IIQ Appendix 4C & Quarterly Activities Report - June 2022
- IIQ Investor Presentation
- 2022 Annual Report and update on results
- INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform
- Receipt of R&D Tax Incentive Refund
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq